Sun Pharmaceutical Industries plans to raise $1.04 billion through a rupee-denominated debt sale to refinance a bridge loan for its acquisition of Organon & Co.

Explore how new cholesterol-lowering therapies, including PCSK9 inhibitors and oral options, are changing the landscape of ...

Novo Nordisk secures licensing rights to Hengrui's experimental GLP-1 pill for weight management, enhancing its portfolio in ...

The deal, gives Merck access to SPR2015, an oral drug candidate targeting KRAS G12D, one of the most common cancer-driving ...

Swiss pharmaceutical leader Roche reveals ambitious plans to establish autonomous AI labs aimed at expediting research and ...

BioNTech, the German COVID-19 vaccine maker, is set to close its sites in Germany and Singapore after failing to secure ...

A federal judge has rejected efforts by Pfizer, BioNTech, and Moderna to dismiss Bayer's patent lawsuit related to mRNA technology used in COVID-19 vaccines. This ruling highlights ongoing legal ...

India Ratings and Research forecasts a 10% growth for the Indian pharmaceutical industry in FY27, supported by strong ...

Lupin Limited has received tentative approval from the FDA to market a generic version of Eliquis, a leading blood thinner ...

Eli Lilly has gained FDA approval for Olumiant to treat severe alopecia areata in children aged 12 and over, marking a ...

The decision followed discussions with the US Food and Drug Administration, which determined that the data from a mid-stage ...

Sun Pharmaceuticals acquires rights to manufacture and market Lyrokaul, a novel PCSK9 inhibitor, enhancing treatment options for cholesterol management. Discover its benefits and market implications.